Hormonal Contraceptive Market Size, Share & Trends Report

Hormonal Contraceptive Market Size, Share & Trends Analysis Report By Method (Pill, Intrauterine Device (IUD), Patch, Implant, Vaginal Ring, Injectable), By Region, Vendor Landscape, And Segment Forecasts, 2018 - 2025

  • Published Date: Mar, 2018
  • Base Year for Estimate: 2016
  • Report ID: GVR-2-68038-348-5
  • Format: Electronic (PDF)
  • Historical Data: 2014 - 2015
  • Number of Pages: 100

Industry Outlook

The global hormonal contraceptive market size was valued at USD 18.4 billion in 2016. It is projected to experience a CAGR of 4.0% over the forecast period. Rising awareness regarding contraception methods in emerging countries, increasing investments by market players to develop innovative devices, and supportive government initiatives to improve access are key trends accelerating market growth.

U.S. hormonal contraceptive market

Partnerships & collaborations between players for R&D activities and commercialization of new products are among key strategies adopted by them to increase their market share. For instance, Medicines 360 and Allergan announced partnership with health centers to help address unintended pregnancies in areas impacted by Zika, such as Puerto Rico and Florida, in February 2017. The partnership helped in increasing access to a hormonal contraceptive - Levonorgestrel-releasing Intrauterine System (LILETTA) - of the company in the region, which is indicated to prevent of pregnancy for up to 3 years.

Awareness programs by governments and market players help augment demand, and thereby, market for contraceptives. For instance, in July 2015, Teva Pharmaceutical Industries Ltd launched an educational initiative, “Perfectly Imperfect” to create awareness about emergency contraception. In addition, in September 2015, Allergan announced partnership with the U.S. Women's Health Alliance (USWHA), which is an organization that focuses on promoting affordable and high-quality healthcare services for women. This agreement will make LILETTA, an intrauterine device of Allergan, available to women across USWHA Health Care Groups in the U.S.

Introduction of long-acting reversible devices in the market is one of the major driving factors. For instance, in September 2016, Bayer Inc. launched Kyleena, a new Intrauterine System (IUS), to prevent pregnancy. Launch of Kyleena is anticipated to help address the need for long-term contraception in women for up to 5 years.

Method Insights

On the basis of method, the market has been segmented into pill, intrauterine device (IUD), injectable, vaginal ring, implant, and patch. In 2016, contraceptive pills accounted for the largest market share. It is estimated to maintain its dominance throughout the forecast period.

The growth of the segment can be attributed to easy & simple mode of administration, easy availability of a wide range, high awareness about pills due to early market entry compared to long-acting devices, and high efficiency of about 99% on timely consumption. Furthermore, presence of various major market players in the field and growing penetration in emerging countries are poised to contribute to the growth of the segment.

Global hormonal contraceptive market

IUDs are likely to observe fastest growth during the forecast period due to increasing adoption of long-acting methods of contraception. Factors attributable for the noteworthy growth of the segment are more than 99.0% effectivity, longer action span, no effect of the device on breastfeeding, and normal fertility after removal of device.

Long-acting birth control methods such as IUD and vaginal rings have become more popular in the U.S. Since the last decade, their adoption is on a rise. This can be due to steady increase in copay for oral contraceptive pills and subsequently, improving affordability. Major IUD’s currently available in the U.S. market are Kyleena, Mirena, Skyla, and Liletta.

Regional Insights

North America dominated the global hormonal contraceptive market in 2016. The region is expected to retain its position throughout the forecast period. This can be attributed to high per capita income, strong presence of key market players, higher awareness about sexual health, and large number of unintended pregnancies.

Asia Pacific is projected to witness the fastest growth during the forecast period. Large fertile population, introduction of new female contraception devices, rise in investment by market players, and strong economic growth are the major factors supplementing the growth of the region.

Rising number of product launches, favorable government initiatives, and increasing awareness among population is anticipated to propel the Middle East and Africa market. For instance, in May 2013, Merck & Co. and its public sector partners extended the agreement to expand access to Implanon. As per this agreement, the company was to reduce the price of the implant and its next-generation drug Implanon NXT (etonogestrel) by approximately 50% for the next 6 years in 70 poor countries.

Hormonal Contraceptive Market Share Insights

The market is fragmented in nature due to presence of several generic drugs. Major players operating in the market are Allergan; Afaxys, Inc.; Teva Pharmaceuticals Industries Ltd.; Bayer AG; Merck & Co. Inc.; Pfizer; Agile Therapeutics; and Apothecus Pharmaceutical Corporation.

Approval & commercialization of various products and expanding geographical reach are major strategies adopted by industry participants to enhance their market share. For instance, in March 2017, TEVA launched generics of Minastrin 24 Fe-ethinyl estradiol & norethindrone acetate tablets and ferrous fumarate tablets, used as an oral contraceptive in the U.S.

Report Scope



Base year for estimation


Actual estimates/Historical data

2014 - 2015

Forecast period

2017 - 2025

Market representation                         

Revenue in USD Million and CAGR from 2017 to 2025

Regional scope

North America, Europe, Asia Pacific, Latin America, Middle East & Africa

Country scope

U.S., Canada, Germany, U.K., China, Japan, Brazil, Mexico, South Africa

Report coverage  

Revenue forecast, competitive landscape, growth factors and trends

15% free customization scope (equivalent to 5 analyst working days)

If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization

Segments Covered in the Report

This report forecasts revenue growth at global, regional, & country levels and provides an analysis on industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the global hormonal contraceptive market report on the basis of method and region:

  • Method Outlook (Revenue, USD Million, 2014 - 2025)

    • Pill

    • Intrauterine Device (IUD)

    • Injectable

    • Vaginal Ring

    • Implant

    • Patch

  • Regional Outlook (Revenue, USD Million, 2014 - 2025)

    • North America

      • U.S.

      • Canada

    • Europe

      • U.K.

      • Germany

    • Asia Pacific

      • China

      • Japan

    • Latin America

      • Brazil

      • Mexico

    • Middle East & Africa

      • South Africa

Key questions answered by the report
Request for Customization

Choose License Type

Single User - $4,950
Multi User (2-5) - $5,950
Enterprise Access - $7,950

Buy Chapters or Sections

Avail customized purchase options to meet your exact research needs:

  • Buy sections of this report
  • Buy country level reports
  • Request for historical data
  • Request discounts available for Start-Ups & Universities

Why Choose Us

  • Research support

    24/5 Research support

    Get your queries resolved from an industry expert.

  • Custom research service

    Custom research service

    Design an exclusive study to serve your research needs.

  • Quality assurance

    Quality assurance

    A testimonial for service in the form of BBB "A" Accreditation.

  • BBB Rating dandb
  • Information security

    Information security

    Your personal and confidential information is safe and secure.

  • grand view research PCI DSS complaint grand view research paypal verified